Hiromi Kumon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiromi Kumon has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Oyama
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
1 shared publication - Daisuke Uchida
Okayama University Hospital, Japan
1 shared publication - Eiji Matsuura
Okayama University
1 shared publication - Emi Tanaka
Department of Gastroenterology Japanese Red Cross Himeji Hospital Himeji Japan
1 shared publication - Hidenori Shiraha
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
1 shared publication - Hironari Kato
Department of Gastroenterology and Hepatology Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
1 shared publication
Latest Publications
- 24 June 2020
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 20 (1) , 64-70
Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer
Background: We previously demonstrated that the reduced expression in immortalized cells (REIC)/dikkopf-3 (Dkk-3) gene was downregulated in various malignant tumors, and that an adenovirus vector carrying the REIC/Dkk-3 gene, termed Ad-REIC induced cancer-selective apoptosis in pancreatic cancer and hepatocellular carcinoma. Objective: In this study, we examined the therapeutic effects of Ad-REIC in biliary cancer using a second- generation Ad-REIC (Ad-SGE-REIC). Methods: Human biliary cancer cell lines (G-415, TFK-1) were used in this study. The cell viability and apoptotic effect of Ad-SGE-REIC were assessed in vitro using an MTT assay and Hoechst staining. The anti-tumor effect in vivo was assessed in a mouse xenograft model. We also assessed the therapeutic effects of Ad-SGE-REIC therapy with cisplatin. Cell signaling was assessed by Western blotting. Results: Ad-SGE-REIC reduced cell viability, and induced apoptosis in biliary cancer cell lines via the activation of the c-Jun N-terminal kinase pathway. Ad-SGE-REIC also inhibited tumor growth in a mouse xenograft model. This effect was further enhanced in combination with cisplatin. Conclusions: Ad-SGE-REIC induced apoptosis and inhibited tumor growth in biliary cancer cells. REIC/Dkk-3 gene therapy using Ad-SGE-REIC is an attractive therapeutic tool for biliary cancer.
- 24 June 2020
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 20 (1) , 64-70
Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer
Background: We previously demonstrated that the reduced expression in immortalized cells (REIC)/dikkopf-3 (Dkk-3) gene was downregulated in various malignant tumors, and that an adenovirus vector carrying the REIC/Dkk-3 gene, termed Ad-REIC induced cancer-selective apoptosis in pancreatic cancer and hepatocellular carcinoma. Objective: In this study, we examined the therapeutic effects of Ad-REIC in biliary cancer using a second- generation Ad-REIC (Ad-SGE-REIC). Methods: Human biliary cancer cell lines (G-415, TFK-1) were used in this study. The cell viability and apoptotic effect of Ad-SGE-REIC were assessed in vitro using an MTT assay and Hoechst staining. The anti-tumor effect in vivo was assessed in a mouse xenograft model. We also assessed the therapeutic effects of Ad-SGE-REIC therapy with cisplatin. Cell signaling was assessed by Western blotting. Results: Ad-SGE-REIC reduced cell viability, and induced apoptosis in biliary cancer cell lines via the activation of the c-Jun N-terminal kinase pathway. Ad-SGE-REIC also inhibited tumor growth in a mouse xenograft model. This effect was further enhanced in combination with cisplatin. Conclusions: Ad-SGE-REIC induced apoptosis and inhibited tumor growth in biliary cancer cells. REIC/Dkk-3 gene therapy using Ad-SGE-REIC is an attractive therapeutic tool for biliary cancer.
- Open Access
- 6 December 2012
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 298 (1) , 295-300
A purification system for 64Cu produced by a biomedical cyclotron for antibody PET imaging
Ion exchange is a simple and efficient method for separating no-carrier-added 64Cu from an irradiated Ni target. We developed a semi-automated two-round 64Cu separation system equipped with a strong-base anion exchange resin column. We first verified the efficiency of the system using a non-radioactive substitute consisting of 25 mg of Ni and 127 ng of Cu, and confirmed that Cu was completely eluted at the second round of the separation step. After the bombardment, separation of 64Cu from the Ni target was achieved with high radiochemical purity. 64Cu produced and separated in this study had an extremely low level of Ni impurity. It could be used for labeling monoclonal antibodies for antibody positron emission tomography imaging and synthesizing radiopharmaceuticals.
- 6 December 2012
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 298 (1) , 295-300
Open AccessA purification system for 64Cu produced by a biomedical cyclotron for antibody PET imaging
Ion exchange is a simple and efficient method for separating no-carrier-added 64Cu from an irradiated Ni target. We developed a semi-automated two-round 64Cu separation system equipped with a strong-base anion exchange resin column. We first verified the efficiency of the system using a non-radioactive substitute consisting of 25 mg of Ni and 127 ng of Cu, and confirmed that Cu was completely eluted at the second round of the separation step. After the bombardment, separation of 64Cu from the Ni target was achieved with high radiochemical purity. 64Cu produced and separated in this study had an extremely low level of Ni impurity. It could be used for labeling monoclonal antibodies for antibody positron emission tomography imaging and synthesizing radiopharmaceuticals.
- 1 January 2002
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 8 (2) , 168-174
Molecular epidemiological studies of Staphylococcus aureus in urinary tract infection
- 1 January 2002
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 8 (2) , 168-174
Molecular epidemiological studies of Staphylococcus aureus in urinary tract infection
- 1 November 2000
- Published by Wiley in BJU International
- Vol. 86 (7) , 802-804
The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer
Objectives To assess the validity of the prophylactic use of pirarubicin ([2′R]‐4‐O‐tetrahydropyranyl‐doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side‐effects.
- 1 November 2000
- Published by Wiley in BJU International
- Vol. 86 (7) , 802-804
The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer
Objectives To assess the validity of the prophylactic use of pirarubicin ([2′R]‐4‐O‐tetrahydropyranyl‐doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side‐effects.